Series C funding round for NiKang Therapeutics raising $200M in May 2021
Series C funding round for NiKang Therapeutics raising $200M in May 2021
| Investor | Firm Type | Partner |
|---|
| Venture Capital | — | |
Hbm PartnersLEAD | Venture Capital | — |
Octagon CapitalLEAD | Venture Capital | — |
| Private | — | |
| Private | — | |
| Venture Capital | — | |
| Hedge Fund | — | |
| Private | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Hedge Fund | — | |
| Venture Capital | — | |
| Private | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Venture Capital | — | |
| Private | — | |
| Venture Capital | — | |
| Private | — | |
| Venture Capital | — | |
| Venture Capital | — |
This company has completed 2 funding rounds. Current round is highlighted.
Total Raised
$250M
Top Valuation
-
NiKang Therapeutics raised $200M in a Series C round.
The round was announced on 05/01/21.
The round was led by Cormorant Asset Management, HBM Healthcare Investments, Ting Jia (TJ).